GPC3 and neoplasm: As specifically recognized by glypican-3 (GPC3) acceptors that overexpressed in tumor cells (L. Dong et al., 2018; Zhao et al., 2018), AP613-1 aptamers could trigger the degradation of H-MnO2-SRF-APT in the TME but are dormant when no GPC3 was encountered.